Study of Novel Types of Familial Diabetes Insipidus

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.

Verified February 2006 by Office of Rare Diseases (ORD).
Recruitment status was: Active, not recruiting

Sponsor:

ClinicalTrials.gov Identifier:

NCT00004364

First Posted: October 19, 1999

Last Update Posted: February 22, 2006

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.

Collaborator:

Northwestern University

Information provided by:

Office of Rare Diseases (ORD)

Purpose

OBJECTIVES:

I. Define the phenotype and genotype of previously unrecognized types of familial diabetes insipidus (FDI) in kindreds with atypical or novel forms of FDI.

Condition	Intervention
Diabetes Insipidus	Drug: desmopressin


Study Type:	Observational
Study Design:	Primary Purpose: Screening

Resource links provided by NLM:

Genetics Home Reference related topics: neurohypophyseal diabetes insipidus

MedlinePlus related topics: Diabetes Insipidus

Drug Information available for: Desmopressin Desmopressin acetate

U.S. FDA Resources

Further study details as provided by Office of Rare Diseases (ORD):


Estimated Enrollment:	5
Study Start Date:	December 1995

Detailed Description:

PROTOCOL OUTLINE: Participants undergo a series of tests to determine the presence, absence, cause, natural history, clinical status, and mode of inheritance of their type of diabetes insipidus (DI). The studies include measurements of basal fluid intake and urine output, plasma vasopressin during standard fluid deprivation or waterload/saline infusion tests, and changes in water balance during a therapeutic trial of DDAVP. If clinically indicated, echocardiograms and assays of plasma catecholes and renin are also completed.

Linkage analysis is performed for all participants; kindreds with the Marfan-like syndrome are also studied for the fibrillin-1 genotype.

Participants determined to have DI are treated with desmopressin for 2 days.

Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:	6 Months to 70 Years (Child, Adult, Senior)
Sexes Eligible for Study:	All
Accepts Healthy Volunteers:	No

Criteria

Familial diabetes insipidus (DI) in atypical or novel form, e.g.: Dipsogenic DI Neurohypophyseal DI
Affected and unaffected members of kindreds eligible

Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00004364

Sponsors and Collaborators

National Center for Research Resources (NCRR)

Northwestern University

Investigators


Study Chair:	Gary L. Robertson	Northwestern University

More Information


ClinicalTrials.gov Identifier:	NCT00004364 History of Changes
Other Study ID Numbers:	199/11939 NU-570
First Submitted:	October 18, 1999
First Posted:	October 19, 1999
Last Update Posted:	February 22, 2006
Last Verified:	February 2006

Keywords provided by Office of Rare Diseases (ORD):


diabetes insipidus endocrine disorders rare disease

Additional relevant MeSH terms:


Diabetes Insipidus Kidney Diseases Urologic Diseases Pituitary Diseases Endocrine System Diseases Deamino Arginine Vasopressin Arginine Vasopressin	Hemostatics Coagulants Antidiuretic Agents Natriuretic Agents Physiological Effects of Drugs Vasoconstrictor Agents

To Top